1. Cancer Biology
Download icon

Squamous trans-differentiation of pancreatic cancer cells promotes stromal inflammation

  1. Tim DD Somerville
  2. Giulia Biffi
  3. Juliane Daßler-Plenker
  4. Stella K Hur
  5. Xue-Yan He
  6. Krysten E Vance
  7. Koji Miyabayashi
  8. Yali Xu
  9. Diogo Maia-Silva
  10. Olaf Klingbeil
  11. Osama E Demerdash
  12. Jonathan B Preall
  13. Michael A Hollingsworth
  14. Mikala Egeblad
  15. David A Tuveson
  16. Christopher R Vakoc  Is a corresponding author
  1. Cold Spring Harbor Laboratory, United States
  2. University of Nebraska, United States
  3. University of Nebraska Medical Center, United States
Research Article
  • Cited 7
  • Views 3,079
  • Annotations
Cite this article as: eLife 2020;9:e53381 doi: 10.7554/eLife.53381

Abstract

A highly aggressive subset of pancreatic ductal adenocarcinomas undergo trans-differentiation into the squamous lineage during disease progression. Here, we investigated whether squamous trans-differentiation of human and mouse pancreatic cancer cells can influence the phenotype of non-neoplastic cells in the tumor microenvironment. Conditioned media experiments revealed that squamous pancreatic cancer cells secrete factors that recruit neutrophils and convert pancreatic stellate cells into cancer-associated fibroblasts (CAFs) that express inflammatory cytokines at high levels. We use gain- and loss-of-function approaches to show that squamous-subtype pancreatic tumor models become enriched with neutrophils and inflammatory CAFs in a p63-dependent manner. These effects occur, at least in part, through p63-mediated activation of enhancers at pro-inflammatory cytokine loci, which includes IL1A and CXCL1 as key targets. Taken together, our findings reveal enhanced tissue inflammation as a consequence of squamous trans-differentiation in pancreatic cancer, thus highlighting an instructive role of tumor cell lineage in reprogramming the stromal microenvironment.

Article and author information

Author details

  1. Tim DD Somerville

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  2. Giulia Biffi

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  3. Juliane Daßler-Plenker

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  4. Stella K Hur

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  5. Xue-Yan He

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  6. Krysten E Vance

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska, Omaha, United States
    Competing interests
    No competing interests declared.
  7. Koji Miyabayashi

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  8. Yali Xu

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  9. Diogo Maia-Silva

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  10. Olaf Klingbeil

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  11. Osama E Demerdash

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  12. Jonathan B Preall

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  13. Michael A Hollingsworth

    Eppley Institute, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  14. Mikala Egeblad

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    No competing interests declared.
  15. David A Tuveson

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    Competing interests
    David A Tuveson, an advisor to Surface, Leap, and Cygnal and has stock ownership in Surface and Leap.
  16. Christopher R Vakoc

    Cancer and Molecular Biology, Cold Spring Harbor Laboratory, Cold Spring Harbor, United States
    For correspondence
    vakoc@cshl.edu
    Competing interests
    Christopher R Vakoc, has received funding from Boehringer-Ingelheim and is an advisor to KSQ Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1158-7180

Funding

New York State Department of Health (C150158)

  • Tim DD Somerville

National Cancer Institute (U10CA180944)

  • David A Tuveson

National Cancer Institute (U01CA210240)

  • David A Tuveson

National Cancer Institute (U01CA224013)

  • David A Tuveson

National Cancer Institute (1R01CA188134)

  • David A Tuveson

National Cancer Institute (1R01CA190092)

  • David A Tuveson

Pershing Square Foundation

  • Christopher R Vakoc

National Cancer Institute (5P01CA013106-Project 4)

  • Christopher R Vakoc

National Cancer Institute (CA229699)

  • Christopher R Vakoc

Pancreatic Cancer Action Network (16-20-25-VAKO)

  • Christopher R Vakoc

Lustgarten Foundation

  • David A Tuveson

National Cancer Institute (5P30CA45508)

  • David A Tuveson

National Cancer Institute (5P50CA101955)

  • David A Tuveson

National Cancer Institute (P20CA192996)

  • David A Tuveson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All animal procedures and studies were approved by the Cold Spring Harbor Laboratory Animal Care and Use Committee (IACUC protocol number 19-16-8).

Reviewing Editor

  1. Charles L Sawyers, Memorial Sloan Kettering Cancer Center, United States

Publication history

  1. Received: November 6, 2019
  2. Accepted: April 23, 2020
  3. Accepted Manuscript published: April 24, 2020 (version 1)
  4. Version of Record published: May 5, 2020 (version 2)
  5. Version of Record updated: May 12, 2020 (version 3)

Copyright

© 2020, Somerville et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,079
    Page views
  • 486
    Downloads
  • 7
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Kenichi Shimada et al.
    Tools and Resources Updated

    Individual cancers rely on distinct essential genes for their survival. The Cancer Dependency Map (DepMap) is an ongoing project to uncover these gene dependencies in hundreds of cancer cell lines. To make this drug discovery resource more accessible to the scientific community, we built an easy-to-use browser, shinyDepMap (https://labsyspharm.shinyapps.io/depmap). shinyDepMap combines CRISPR and shRNA data to determine, for each gene, the growth reduction caused by knockout/knockdown and the selectivity of this effect across cell lines. The tool also clusters genes with similar dependencies, revealing functional relationships. shinyDepMap can be used to (1) predict the efficacy and selectivity of drugs targeting particular genes; (2) identify maximally sensitive cell lines for testing a drug; (3) target hop, that is, navigate from an undruggable protein with the desired selectivity profile, such as an activated oncogene, to more druggable targets with a similar profile; and (4) identify novel pathways driving cancer cell growth and survival.

    1. Cancer Biology
    2. Neuroscience
    Zhi Zhang et al.
    Research Article

    Adjuvant tamoxifen therapy improves survival in breast cancer patients. Unfortunately, long-term treatment comes with side effects that impact health and quality of life, including hot flashes, changes in bone density, and fatigue. Partly due to a lack of proven animal models, the tissues and cells that mediate these negative side effects are unclear. Here, we show that mice undergoing tamoxifen treatment experience changes in temperature, bone, and movement. Single-cell RNA sequencing reveals that tamoxifen treatment induces widespread gene expression changes in the hypothalamus and preoptic area (hypothalamus-POA). These expression changes are dependent on estrogen receptor alpha (ERα), as conditional knockout of ERα in the hypothalamus-POA ablates or reverses tamoxifen-induced gene expression. Accordingly, ERα-deficient mice do not exhibit tamoxifen-induced changes in temperature, bone, or movement. These findings provide mechanistic insight into the effects of tamoxifen on the hypothalamus-POA and indicate that ERα mediates several physiological effects of tamoxifen treatment in mice.